{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-008264","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.191213+00:00","generated_at":"2026-06-05T07:43:28.685501+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Enveric signs non-binding term sheets to out-license three compound classes; potential $200M milestones","bullets":["Three non-binding term sheets signed with undisclosed biotech for exclusive global out-licenses of three compound classes.","Potential total milestone payments and execution fees up to $200M if all development and sales criteria are met.","Royalty rates on each license range from 2.5% to 10% on future sales depending on criteria.","Compounds from Enveric's Psybrary platform library of over 1,000 novel molecules generated using AI drug discovery.","Licensee assumes all future preclinical and clinical development costs for human/animal applications."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-008264","json":"https://secwatch.observer/filing/0001493152-24-008264.json","markdown":"https://secwatch.observer/filing/0001493152-24-008264.md","text":"https://secwatch.observer/filing/0001493152-24-008264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315224008264/0001493152-24-008264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315224008264/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:43:28.685501+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}